Targeted therapy reactivates 'guardian of the genome' in resistant cancer
Monday, November 15, 2010 - 13:31
in Health & Medicine
A study demonstrating pharmacological rescue of a key tumor suppressor may lead to new therapeutic strategies for human cancer and significantly broaden the types of tumors that respond to targeted therapy, including those that have been resistant to current treatments. The research, published by Cell Press in the Nov. 16 issue of the journal Cancer Cell, focuses on cancers exhibiting inhibition of p53, a protein that is critical for initiating cell death pathways in abnormal cells.